OraPharma, Inc. Continues its Commitment to Academic Community
by Renewing the ARESTIN® Student Access Program for the Fourth Year
Innovative Program Continues to Supply an Increasing Number of Dental and Dental Hygiene Schools with Product and Course Materials for ARESTIN® Hands-On Instruction
Warminster, PA – September 08, 2010 – OraPharma, Inc., a specialty oral health company dedicated to bringing scientifically and technologically advanced products to the dental community, including ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg, is continuing its commitment to providing educational support and training to dental and dental hygiene schools by renewing the ARESTIN® Student Access Program for the fourth consecutive year.
The ARESTIN® Student Access Program was implemented in 2007 as the result of discussion and collaboration between OraPharma and the course directors of leading dental and dental hygiene school programs and continues to expand. According to OraPharma’s Professional Educator, Debbie Rosema, RDH, BSDH, “Our continuing mission is to provide educational programming and hands-on training so that dental and dental hygiene students can learn how to appropriately incorporate locally administered antibiotics like ARESTIN® as part of a comprehensive periodontal disease treatment protocol.”
Since its inception in 2007, more than 250 dental and dental hygiene schools and over 10,000 dental and dental hygiene students have participated in the ARESTIN® Student Access Program.
Enrollment for the 2010-2011 program is still available to all accredited two- or four-year dental and dental hygiene schools as well as periodontal specialty programs that include instruction on the use of ARESTIN® as part of a comprehensive periodontal treatment protocol. Participating schools will receive the following ARESTIN® Student Access Program materials:
ARESTIN® Trial Kits containing 12 ARESTIN® cartridges for non-reimbursable clinical use by each participating senior student.
Faculty Education Kits containing important educational, clinical and patient resources regarding periodontal therapy and ARESTIN®, as well as content for classroom lectures and demonstration product for hands on laboratory use to ensure each student is able to practice placing ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg, prior to treating patients.
• Student Education Kits including important clinical and patient education resources regarding periodontal therapy and ARESTIN®.
Two demonstration ARESTIN® handles and the ability to order additional discounted
ARESTIN® handles for all participating students.
In addition, the OraPharma, Inc Professional Affairs Team can provide enhanced support and introduce additional academic programs to dental and hygiene schools. This team will also provide best practices training and education for course directors in schools participating in the ARESTIN® Student Access Program.
“We’re very pleased with the increased acceptance and continued success of the ARESTIN® Student Access Program,” said Dina Weisleder, ARESTIN® Product Director. “Today’s students represent the next generation of oral health professionals, and it’s important that they have training and experience with the full scope of periodontal disease treatment options when they enter the profession.”
Dental and dental hygiene school faculty who wish to participate in the ARESTIN® Student Access Program can get more information and register for the program at https://www.myarestin.com/studentaccess. If you require more information, please contact Debbie Rosema, RDH, BSDH, Professional Educator at
1-888-553-6010 extension 0627.
About OraPharma, Inc.
OraPharma, Inc. is a specialty pharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of periodontal disease at various phases of progression. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg (www.arestin.com) is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. For more information about OraPharma, Inc. and its products, visit www.orapharma.com.
About ARESTIN®
ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program which includes good oral hygiene, and scaling and root planing.
ARESTIN® contains minocycline, a tetracycline derivative, and therefore should not be used in children and in pregnant or nursing women. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth.
The most common treatment-emergent adverse events were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%). These occurred at a similar rate to SRP and SRP + placebo.
oraPHARMA, INC.
ARESTIN® is a registered trademark of OraPharma, Inc.
© OraPharma, Inc. 2010 A-1050 9/07
